Why GSK’s SBP Group alliance could reshape chronic hepatitis B access in Chin
China has hepatitis B scale. GSK has bepirovirsen. SBP Group may decide whether science can become real-world access.
Akeso’s gumokimab advances to NMPA review in ankylosing spondylitis: Is China’s IL-17 race entering a new phase?
Akeso’s gumokimab enters NMPA review for ankylosing spondylitis after Phase 3 success. Find out what this could mean for IL-17 therapies in China.